Health‐related quality of life · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · alcohol‐related disorders (others)
Propylthiouracil may leads to lower mortality at maximal compared with no intervention (low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term mortality · people with hereditary haemochromatosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
All‐cause mortality · people with hereditary haemochromatosis
1 finding from 1 review
Serious adverse events · people with hereditary haemochromatosis
1 finding from 1 review
Health‐related quality of life EQ‐VAS. Scale from: 0 to 100. · people with hereditary haemochromatosis
1 finding from 1 review
Health‐related quality of life beyond one year · people with hereditary haemochromatosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether ursodeoxycholic acid (UDCA) changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether ciclosporin changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review